WPI 2233 (Tamoxifen 20 mg)

Pill imprint WPI 2233 has been identified as Tamoxifen citrate 20 mg.

Tamoxifen is used in the treatment of breast cancer, metastatic; breast cancer, adjuvant; breast cancer; breast cancer, prevention; breast cancer, male (and more), and belongs to the drug classes hormones/antineoplastics, selective estrogen receptor modulators. There is positive evidence of human fetal risk during pregnancy. Tamoxifen 20 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for WPI 2233

Tamoxifen citrate 20 mg WPI 2233
Tamoxifen citrate 20 mg WPI 2233
Tamoxifen citrate
Imprint:
WPI
2233
Strength:
20 mg
Color:
White
Shape:
Round
Availability:
Prescription only
Drug Class:
Hormones/antineoplastics
Selective estrogen receptor modulators
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
N - Not a controlled drug
Manufacturer:
Watson Pharmaceuticals, Inc.
National Drug Code (NDC):
00591-2233
Inactive Ingredients:
croscarmellose sodium
lactose monohydrate
magnesium stearate
microcrystalline cellulose
pregelatinized corn starch

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web5)